Loading...
•
Jun 30
Quanterix Q2 2025 Earnings Report
Quanterix reported its financial results for the second quarter ended June 30, 2025, highlighting a decrease in revenue and a significant net loss compared to the prior year.
Key Takeaways
Quanterix experienced a challenging second quarter in 2025, with total revenue decreasing by 29% year-over-year to $24.5 million and a net loss of $30.0 million, significantly wider than the $7.4 million loss in the prior year. Despite these financial setbacks, the company completed the acquisition of Akoya Biosciences and made progress on cost reduction targets, aiming for cash flow breakeven in 2026.
Total revenue for Q2 2025 was $24.5 million, a 29% decrease from $34.4 million in Q2 2024.
The company reported a net loss of $30.0 million in Q2 2025, compared to a net loss of $7.4 million in the same period last year.
GAAP gross margin declined to 46.2% from 64.7% in the prior year, while adjusted gross margin was 41.8% compared to 58.6%.
Quanterix ended the quarter with $263.8 million in cash, cash equivalents, marketable securities, and restricted cash, with an adjusted cash usage of $2.6 million.
Quanterix
Quanterix
Quanterix Revenue by Segment
Revenue by Segment
Product Revenue
CapyFin.comService and Other Revenue
CapyFin.comCollaboration and License Revenue
CapyFin.comGrant Revenue
CapyFin.com Forward Guidance
Quanterix provided a full-year 2025 business outlook, anticipating revenues between $130 million and $135 million, including approximately two quarters of Akoya's performance. The company expects GAAP gross margin to be 49% to 53% and adjusted gross margin to be 45% to 49%. Adjusted cash usage is projected to be $34 million to $38 million, with a goal to achieve cash flow breakeven in 2026.
Positive Outlook
- Expected full-year 2025 revenues of $130 million to $135 million, including Akoya's contribution.
- Pro forma revenue for 2025, assuming full-year combination with Akoya, is expected to be $165 million to $170 million.
- Anticipated GAAP gross margin in the range of 49% to 53% for the full year 2025.
- Expected adjusted gross margin in the range of 45% to 49% for the full year 2025.
- Targeting cash flow breakeven in 2026, supported by previously announced expense reductions.
Challenges Ahead
- Recent weakness observed in the U.S. academic and pharmaceutical end markets.
- Projected adjusted cash usage of approximately $34 million to $38 million for 2025.
- The full-year revenue guidance of $130 million to $135 million is lower than the pro forma combined revenue, indicating a partial year contribution from Akoya.
- Achieving cash flow breakeven in 2026 is contingent on end market conditions, which may remain difficult.
- The company's ability to realize anticipated benefits and synergies from the Akoya acquisition is subject to risks.
Revenue & Expenses
Visualization of income flow from segment revenue to net income